Compounding Pharmacy Market Size and Outlook 2030

Report Description

Forecast Period	2026-2030
Market Size (2024)	USD 12.98 Billion
CAGR (2025-2030)	6.52%
Fastest Growing Segment	Pain Management
Largest Market	North America
Market Size (2030)	USD 18.96 Billion

Market Overview

The Global Compounding Pharmacy Market, valued at USD 12.98 Billion in 2024, is projected to experience a CAGR of 6.52% to reach USD 18.96 Billion by 2030. The global compounding pharmacy market encompasses the specialized practice of pharmacists creating tailored medications for individual patients, addressing unique therapeutic requirements that are not fulfilled by mass-produced pharmaceuticals. This customization may involve specific dosage forms, allergen removal, or enhanced palatability. Key drivers supporting market growth include the increasing demand for personalized medicine to accommodate diverse patient needs, the rising incidence of chronic diseases requiring specialized treatments, and the ongoing challenges of drug shortages within the broader pharmaceutical industry. According to the National Community Pharmacists Association, in 2024, 47% of independent community pharmacy respondents offered compounding services.

A significant challenge impeding further market expansion stems from the stringent and evolving regulatory environment surrounding compounded preparations. Varying jurisdictional oversight and compliance requirements for quality assurance and safety can impose considerable operational complexities and financial burdens on compounding pharmacies, potentially impacting their ability to scale and innovate.

Key Market Drivers

The increasing demand for personalized medication is a primary catalyst for the Global Compounding Pharmacy Market. Patients frequently require pharmaceutical formulations precisely adjusted for specific allergies, unique dosage strengths, or alternative administration routes not commercially available. This customization is crucial for optimizing therapeutic outcomes and minimizing adverse reactions, driving demand for tailored solutions. According to the Alliance for Pharmacy Compounding, in their "2023-2024 Compounding Pharmacy Snapshot" published in July 2024, in the median hybrid pharmacy, 30% of all prescriptions were for compounded medications, demonstrating significant reliance on individualized preparations. The broader independent pharmacy sector, a critical component of the compounding market, represented a $94.9 billion marketplace in 2023, according to the National Community Pharmacists Association, underscoring the substantial economic activity linked to these services.

Concurrently, the rising prevalence of chronic diseases significantly propels the need for compounding pharmacies. Conditions such as diabetes, cardiovascular disorders, and complex pain often necessitate long-term, individualized treatment regimens. Many patients with chronic illnesses cannot tolerate standard commercially manufactured drugs due to specific side effects, efficacy limitations, or unique dietary restrictions, making compounded alternatives essential for ongoing care. These pharmacies provide customized solutions that improve drug tolerability and effectiveness for these populations. According to the research article "Medicine Use in Chronic Diseases" published in Pharmacy in June 2023, approximately one in every three adults worldwide suffers from multiple chronic conditions, highlighting a pervasive need for adaptable pharmaceutical interventions.

Download Free Sample Report

Key Market Challenges

The stringent and evolving regulatory environment presents a significant challenge to the global compounding pharmacy market. Varying jurisdictional oversight and complex compliance requirements for quality assurance and safety impose considerable operational complexities and financial burdens on compounding pharmacies. These escalating demands directly impede market expansion by increasing operating costs and diverting resources from potential growth initiatives. For instance, according to the Alliance for Pharmacy Compounding, in Fall 2023, 15% of all surveyed compounding pharmacies ceased hazardous drug compounding due to compliance costs associated with new USP Chapter <800> standards. Such substantial investments in facility upgrades, specialized equipment, and extensive staff training required to meet updated standards can be prohibitive, especially for smaller entities. This financial strain and the administrative burden of navigating diverse and frequently changing regulations limit a pharmacy's ability to scale operations, invest in new technologies, or innovate personalized medicine solutions, directly hampering overall market growth.

Key Market Trends

Advanced Compounding Technology Integration is a key driver for market growth, emphasizing the adoption of automation, robotics, and sophisticated software within compounding pharmacies. This integration aims to enhance precision, reduce the potential for human error, and improve overall operational efficiency, which is crucial for handling complex formulations and increasing production volumes while adhering to stringent quality standards. This trend supports pharmacies in meeting the evolving demands for customized medications. According to the Alliance for Pharmacy Compounding's demographic survey in Fall 2023, 529 unique 503A compounding pharmacies or 503B outsourcing facilities were represented, underscoring the significant number of entities potentially benefiting from these technological advancements. For example, B. Braun announced in September 2025 a $20 million investment to modernize its manufacturing facility, which includes upgrades to pharmacy admixture and compounding operations products.

The Expansion of 503B Outsourcing Facilities represents another significant trend, driven by the increasing need for high-volume, sterile compounded medications within healthcare systems. These facilities operate under rigorous regulatory oversight, enabling them to produce compounded drugs in bulk without patient-specific prescriptions, thereby addressing critical supply chain gaps, particularly during drug shortages. This trend provides hospitals and clinics with a reliable source of quality-assured sterile preparations, alleviating the burden on smaller, traditional compounding pharmacies. The American Society of Health-System Pharmacists reported in July 2023 that there were 309 active, ongoing drug shortages, highlighting a persistent demand for such services. Further demonstrating this trend, Fagron Sterile Services US, a prominent 503B outsourcing partner, announced a major expansion in May 2024 at its Wichita, Kansas, 503B outsourcing campus, involving a 40% increase in square-footage to enhance manufacturing capabilities and increase production capacity.

Segmental Insights

The Pain Management segment represents a key segmental insight for the Global Compounding Pharmacy Market, and it is expected to have the highest growth rate during the forecast period. This rapid growth is primarily driven by the increasing prevalence of chronic diseases, accidents, and cancer, which necessitate personalized pain relief solutions not readily available through commercial medications. Compounding pharmacies offer tailored formulations, including topical analgesics and customized dosages, providing critical alternatives for patients experiencing complex pain conditions or seeking to avoid the side effects and addiction risks associated with traditional oral painkillers. Furthermore, the ability to combine multiple pain-relieving agents in a single dose and offer diverse delivery methods enhances patient convenience and adherence, significantly contributing to the segment's expansion.

Regional Insights

North America maintains its leadership in the global compounding pharmacy market primarily due to its sophisticated healthcare infrastructure and a comprehensive regulatory environment. The region benefits from a robust framework involving bodies like the Food and Drug Administration (FDA) and state boards of pharmacy, alongside key legislation such as the Drug Quality and Security Act, which collectively uphold rigorous quality and safety standards for compounded medications. This strong regulatory foundation, combined with a heightened awareness and substantial demand for personalized medicine, fuels market growth. Additionally, compounding pharmacies in North America play a vital role in mitigating drug shortages and addressing the unique medication requirements of a growing geriatric demographic, further solidifying the region's market position.

Recent Developments

In October 2025, PCCA introduced UniFlow™, a new powder excipient base designed to advance T3/T4 compounding. This innovative product aims to address known formulation challenges associated with highly potent, low-dose active pharmaceutical ingredients like liothyronine sodium (T3) and levothyroxine sodium (T4). UniFlow™ is engineered to improve flow and content uniformity, enhance stability, and significantly reduce preparation time by approximately 50 percent. This launch reflects PCCA’s commitment to providing practical innovations that improve efficiency and accuracy for member pharmacies.

In September 2025, Pete Pharma announced a strategic collaboration with FABRX to introduce advanced pharmaceutical 3D printing technology to the U.S. compounding pharmacy market. This partnership aims to modernize personalized medicine production by offering automation and enhanced customization capabilities. FABRX's M3DIMAKER 3D printing platform, with systems for both research and larger-batch manufacturing, is designed to improve workflow efficiency and enable greater personalization of medications across various therapeutic areas. Pete Pharma is utilizing a "pharmacy-first" business model to ensure accessibility for independent pharmacies and reduce operational burdens.

In August 2025, CompoundLabs, a New Zealand compounding pharmacy, formally announced its partnership with Bova Group, a global leader in veterinary pharmaceutical compounding. This collaboration integrates CompoundLabs into Bova’s international network of veterinary compounding partners. The alliance is set to provide veterinarians across New Zealand with enhanced access to innovative, clinically validated formulations. This strategic move by CompoundLabs allows for the delivery of evidence-based treatments, many developed with veterinary specialists, addressing the need for specialized medications in the region.

In February 2025, a significant research breakthrough was published through a collaboration between FABRX, UCL School of Pharmacy researchers, and the University of Santiago de Compostela. This study marked the world's first successful demonstration of automatic compounding and dispensing of 3D printed personalized medicines within a community pharmacy setting. The research focused on producing and dispensing minoxidil medicines directly to patients, establishing an automated process for tailored dosing. This achievement is expected to be a milestone in advancing patient-specific medications and providing pharmacists with an automated tool for enhanced control in compounding.

Key Market Players

Wedgewood Pharmacy
B. Braun Medical Inc.
Fagron NV
Fresenius Kabi
Clinigen Group PLC
Dougherty's Pharmacy, Inc.
Lorraine's Pharmacy
Rx3 Compounding Pharmacy
Institutional Pharmacy Solutions
Mcguff compounding pharmacy services

By Therapeutic Area	By Route of Administration	By End User	By Region
Pain Management Hormone Replacement Dermal Disorders Nutritional Supplements Other Therapeutic Areas	Oral Topical Parenteral Other Route of Administrations	Humans Veterinary	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Compounding Pharmacy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Compounding Pharmacy Market, By Therapeutic Area:

o Pain Management

o Hormone Replacement

o Dermal Disorders

o Nutritional Supplements

o Other Therapeutic Areas

Compounding Pharmacy Market, By Route of Administration:

o Oral

o Topical

o Parenteral

o Other Route of Administrations

Compounding Pharmacy Market, By End User:

o Humans

o Veterinary

Compounding Pharmacy Market, By Region:

o North America

§ United States

§ Canada

§ Mexico

o Europe

§ France

§ United Kingdom

§ Italy

§ Germany

§ Spain

o Asia Pacific

§ China

§ India

§ Japan

§ Australia

§ South Korea

o South America

§ Brazil

§ Argentina

§ Colombia

o Middle East & Africa

§ South Africa

§ Saudi Arabia

§ UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Compounding Pharmacy Market.

Available Customizations:

Global Compounding Pharmacy Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Global Compounding Pharmacy Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]

Table of content

1. Product Overview

1.1. Market Definition

1.2. Scope of the Market

1.2.1. Markets Covered

1.2.2. Years Considered for Study

1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study

2.2. Baseline Methodology

2.3. Key Industry Partners

2.4. Major Association and Secondary Sources

2.5. Forecasting Methodology

2.6. Data Triangulation & Validation

2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market

3.2. Overview of Key Market Segmentations

3.3. Overview of Key Market Players

3.4. Overview of Key Regions/Countries

3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Compounding Pharmacy Market Outlook

5.1. Market Size & Forecast

5.1.1. By Value

5.2. Market Share & Forecast

5.2.1. By Therapeutic Area (Pain Management, Hormone Replacement, Dermal Disorders, Nutritional Supplements, Other Therapeutic Areas)

5.2.2. By Route of Administration (Oral, Topical, Parenteral, Other Route of Administrations)

5.2.3. By End User (Humans, Veterinary)

5.2.4. By Region

5.2.5. By Company (2024)

5.3. Market Map

6. North America Compounding Pharmacy Market Outlook

6.1. Market Size & Forecast

6.1.1. By Value

6.2. Market Share & Forecast

6.2.1. By Therapeutic Area

6.2.2. By Route of Administration

6.2.3. By End User

6.2.4. By Country

6.3. North America: Country Analysis

6.3.1. United States Compounding Pharmacy Market Outlook

6.3.1.1. Market Size & Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share & Forecast

6.3.1.2.1. By Therapeutic Area

6.3.1.2.2. By Route of Administration

6.3.1.2.3. By End User

6.3.2. Canada Compounding Pharmacy Market Outlook

6.3.2.1. Market Size & Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share & Forecast

6.3.2.2.1. By Therapeutic Area

6.3.2.2.2. By Route of Administration

6.3.2.2.3. By End User

6.3.3. Mexico Compounding Pharmacy Market Outlook

6.3.3.1. Market Size & Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share & Forecast

6.3.3.2.1. By Therapeutic Area

6.3.3.2.2. By Route of Administration

6.3.3.2.3. By End User

7. Europe Compounding Pharmacy Market Outlook

7.1. Market Size & Forecast

7.1.1. By Value

7.2. Market Share & Forecast

7.2.1. By Therapeutic Area

7.2.2. By Route of Administration

7.2.3. By End User

7.2.4. By Country

7.3. Europe: Country Analysis

7.3.1. Germany Compounding Pharmacy Market Outlook

7.3.1.1. Market Size & Forecast

7.3.1.1.1. By Value

7.3.1.2. Market Share & Forecast

7.3.1.2.1. By Therapeutic Area

7.3.1.2.2. By Route of Administration

7.3.1.2.3. By End User

7.3.2. France Compounding Pharmacy Market Outlook

7.3.2.1. Market Size & Forecast

7.3.2.1.1. By Value

7.3.2.2. Market Share & Forecast

7.3.2.2.1. By Therapeutic Area

7.3.2.2.2. By Route of Administration

7.3.2.2.3. By End User

7.3.3. United Kingdom Compounding Pharmacy Market Outlook

7.3.3.1. Market Size & Forecast

7.3.3.1.1. By Value

7.3.3.2. Market Share & Forecast

7.3.3.2.1. By Therapeutic Area

7.3.3.2.2. By Route of Administration

7.3.3.2.3. By End User

7.3.4. Italy Compounding Pharmacy Market Outlook

7.3.4.1. Market Size & Forecast

7.3.4.1.1. By Value

7.3.4.2. Market Share & Forecast

7.3.4.2.1. By Therapeutic Area

7.3.4.2.2. By Route of Administration

7.3.4.2.3. By End User

7.3.5. Spain Compounding Pharmacy Market Outlook

7.3.5.1. Market Size & Forecast

7.3.5.1.1. By Value

7.3.5.2. Market Share & Forecast

7.3.5.2.1. By Therapeutic Area

7.3.5.2.2. By Route of Administration

7.3.5.2.3. By End User

8. Asia Pacific Compounding Pharmacy Market Outlook

8.1. Market Size & Forecast

8.1.1. By Value

8.2. Market Share & Forecast

8.2.1. By Therapeutic Area

8.2.2. By Route of Administration

8.2.3. By End User

8.2.4. By Country

8.3. Asia Pacific: Country Analysis

8.3.1. China Compounding Pharmacy Market Outlook

8.3.1.1. Market Size & Forecast

8.3.1.1.1. By Value

8.3.1.2. Market Share & Forecast

8.3.1.2.1. By Therapeutic Area

8.3.1.2.2. By Route of Administration

8.3.1.2.3. By End User

8.3.2. India Compounding Pharmacy Market Outlook

8.3.2.1. Market Size & Forecast

8.3.2.1.1. By Value

8.3.2.2. Market Share & Forecast

8.3.2.2.1. By Therapeutic Area

8.3.2.2.2. By Route of Administration

8.3.2.2.3. By End User

8.3.3. Japan Compounding Pharmacy Market Outlook

8.3.3.1. Market Size & Forecast

8.3.3.1.1. By Value

8.3.3.2. Market Share & Forecast

8.3.3.2.1. By Therapeutic Area

8.3.3.2.2. By Route of Administration

8.3.3.2.3. By End User

8.3.4. South Korea Compounding Pharmacy Market Outlook

8.3.4.1. Market Size & Forecast

8.3.4.1.1. By Value

8.3.4.2. Market Share & Forecast

8.3.4.2.1. By Therapeutic Area

8.3.4.2.2. By Route of Administration

8.3.4.2.3. By End User

8.3.5. Australia Compounding Pharmacy Market Outlook

8.3.5.1. Market Size & Forecast

8.3.5.1.1. By Value

8.3.5.2. Market Share & Forecast

8.3.5.2.1. By Therapeutic Area

8.3.5.2.2. By Route of Administration

8.3.5.2.3. By End User

9. Middle East & Africa Compounding Pharmacy Market Outlook

9.1. Market Size & Forecast

9.1.1. By Value

9.2. Market Share & Forecast

9.2.1. By Therapeutic Area

9.2.2. By Route of Administration

9.2.3. By End User

9.2.4. By Country

9.3. Middle East & Africa: Country Analysis

9.3.1. Saudi Arabia Compounding Pharmacy Market Outlook

9.3.1.1. Market Size & Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share & Forecast

9.3.1.2.1. By Therapeutic Area

9.3.1.2.2. By Route of Administration

9.3.1.2.3. By End User

9.3.2. UAE Compounding Pharmacy Market Outlook

9.3.2.1. Market Size & Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share & Forecast

9.3.2.2.1. By Therapeutic Area

9.3.2.2.2. By Route of Administration

9.3.2.2.3. By End User

9.3.3. South Africa Compounding Pharmacy Market Outlook

9.3.3.1. Market Size & Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share & Forecast

9.3.3.2.1. By Therapeutic Area

9.3.3.2.2. By Route of Administration

9.3.3.2.3. By End User

10. South America Compounding Pharmacy Market Outlook

10.1. Market Size & Forecast

10.1.1. By Value

10.2. Market Share & Forecast

10.2.1. By Therapeutic Area

10.2.2. By Route of Administration

10.2.3. By End User

10.2.4. By Country

10.3. South America: Country Analysis

10.3.1. Brazil Compounding Pharmacy Market Outlook

10.3.1.1. Market Size & Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share & Forecast

10.3.1.2.1. By Therapeutic Area

10.3.1.2.2. By Route of Administration

10.3.1.2.3. By End User

10.3.2. Colombia Compounding Pharmacy Market Outlook

10.3.2.1. Market Size & Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share & Forecast

10.3.2.2.1. By Therapeutic Area

10.3.2.2.2. By Route of Administration

10.3.2.2.3. By End User

10.3.3. Argentina Compounding Pharmacy Market Outlook

10.3.3.1. Market Size & Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share & Forecast

10.3.3.2.1. By Therapeutic Area

10.3.3.2.2. By Route of Administration

10.3.3.2.3. By End User

11. Market Dynamics

11.1. Drivers

11.2. Challenges

12. Market Trends & Developments

12.1. Merger & Acquisition (If Any)

12.2. Product Launches (If Any)

12.3. Recent Developments

13. Global Compounding Pharmacy Market: SWOT Analysis

14. Porter's Five Forces Analysis

14.1. Competition in the Industry

14.2. Potential of New Entrants

14.3. Power of Suppliers

14.4. Power of Customers

14.5. Threat of Substitute Products

15. Competitive Landscape

15.1. Wedgewood Pharmacy

15.1.1. Business Overview

15.1.2. Products & Services

15.1.3. Recent Developments

15.1.4. Key Personnel

15.1.5. SWOT Analysis

15.2. B. Braun Medical Inc.

15.3. Fagron NV

15.4. Fresenius Kabi

15.5. Clinigen Group PLC

15.6. Dougherty's Pharmacy, Inc.

15.7. Lorraine's Pharmacy

15.8. Rx3 Compounding Pharmacy

15.9. Institutional Pharmacy Solutions

15.10. Mcguff compounding pharmacy services

16. Strategic Recommendations

17. About Us & Disclaimer

Report Description

Table of content

Figures and Tables

Frequently asked questions

What was the market size of the Global Compounding Pharmacy Market in 2024?

Which is the dominating region in the Global Compounding Pharmacy Market?

Which is the fastest growing segment in the Global Compounding Pharmacy Market?

What is the expected growth rate of the Global Compounding Pharmacy Market?